ArticleMicroorganisms2022
Management of a Major Carbapenem-Resistant
Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- From Screening to Outcomes: Fourteen-Year Hospital-Wide Surveillance of Alert Pathogens and Antimicrobial Use in a Paediatric Tertiary Hospital.Antibiotics (Basel, Switzerland) · 2026Article
- Tracking Multidrug Resistance in Gram-Negative Bacteria in Alexandria, Egypt (2020-2023): An Integrated Analysis of Patient Data and Diagnostic Tools.Antibiotics (Basel, Switzerland) · 2024Article
- A Systematic Review and Meta-Analysis of Molecular Characteristics on Colistin Resistance ofDiagnostics (Basel, Switzerland) · 2024Review
- AN OUTBREAK OF EXTENSIVELY DRUG-RESISTANTAnnals of burns and fire disasters · 2024Article
- Prevalence and risk factors ofF1000Research · 2024Article
- Molecular Epidemiological Investigation and Management of Outbreak Caused by Carbapenem-ResistantMicroorganisms · 2023Article
- Colistin Resistance inAntibiotics (Basel, Switzerland) · 2023Review
- Control of Healthcare-Associated Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe bundle measures implemented to overcome a protracted carbapenem-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.